Otsuka (OTCMKTS:OTSKY) Shares Gap Down – Here’s What Happened

Otsuka Holdings Co., Ltd. – Unsponsored ADR (OTCMKTS:OTSKY) gapped down before the market opened on Tuesday . The stock had previously closed at $33.12, but opened at $31.4492. Otsuka shares last traded at $32.09, with a volume of 3,057 shares traded.

Analysts Set New Price Targets

A number of research firms have commented on OTSKY. The Goldman Sachs Group downgraded shares of Otsuka from a “strong-buy” rating to a “strong sell” rating in a research note on Friday, February 27th. Zacks Research upgraded shares of Otsuka from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 31st. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold”.

Otsuka Stock Down 0.7%

The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.67 and a current ratio of 2.17. The stock’s fifty day simple moving average is $34.83 and its two-hundred day simple moving average is $32.25. The company has a market capitalization of $34.06 billion and a price-to-earnings ratio of 13.38.

Otsuka (OTCMKTS:OTSKY) last announced its earnings results on Tuesday, April 28th. The company reported $0.59 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.43 by $0.16. Otsuka had a return on equity of 12.33% and a net margin of 15.01%.The company had revenue of $3.96 billion for the quarter, compared to analyst estimates of $3.78 billion. Otsuka has set its FY 2026 guidance at 1.610-1.610 EPS. On average, sell-side analysts anticipate that Otsuka Holdings Co., Ltd. – Unsponsored ADR will post 1.99 EPS for the current year.

About Otsuka

Otsuka Pharmaceutical Co, Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.

Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades.